Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.65 $23,151 - $63,666
38,586 New
38,586 $28,000
Q1 2023

May 15, 2023

BUY
$4.89 - $12.27 $957,550 - $2.4 Million
195,818 New
195,818 $961,000
Q2 2022

Aug 15, 2022

BUY
$7.45 - $13.84 $195,301 - $362,815
26,215 New
26,215 $239,000
Q1 2022

May 16, 2022

SELL
$9.94 - $12.65 $143,623 - $182,779
-14,449 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$11.99 - $18.14 $17,373 - $26,284
1,449 Added 11.15%
14,449 $176,000
Q3 2021

Nov 15, 2021

BUY
$11.55 - $16.06 $150,150 - $208,779
13,000 New
13,000 $201,000
Q2 2021

Aug 16, 2021

SELL
$12.38 - $29.19 $132,020 - $311,282
-10,664 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$15.07 - $21.71 $160,706 - $231,515
10,664 New
10,664 $232,000
Q4 2020

Feb 16, 2021

SELL
$12.72 - $16.16 $397,258 - $504,692
-31,231 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$12.34 - $17.92 $385,390 - $559,659
31,231 New
31,231 $397,000
Q2 2020

Aug 14, 2020

SELL
$12.39 - $17.33 $138,706 - $194,009
-11,195 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$9.12 - $17.78 $283,258 - $552,229
-31,059 Reduced 73.51%
11,195 $148,000
Q4 2019

Feb 14, 2020

BUY
$16.11 - $25.98 $513,216 - $827,644
31,857 Added 306.41%
42,254 $681,000
Q3 2019

Nov 14, 2019

BUY
$18.28 - $26.91 $190,057 - $279,783
10,397 New
10,397 $190,000
Q4 2018

Feb 14, 2019

SELL
$12.45 - $23.47 $121,935 - $229,865
-9,794 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$17.57 - $23.95 $172,080 - $234,566
9,794 New
9,794 $235,000
Q1 2018

May 15, 2018

SELL
$11.77 - $16.08 $1.04 Million - $1.42 Million
-88,566 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$11.86 - $14.08 $1.05 Million - $1.25 Million
88,566
88,566 $1.08 Million

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14.5M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.